肝癌细胞免疫治疗进展

Abstract

Abstract: At present,surgery-based comprehensive therapy plays a dominant role in the treatment of hepatocellular carcinma (HCC).However,the majority of patients had no opportunity to undergo surgical treatment when diagnosis was confirmed.Furthermore,there is a high risk of tumor recurrence for patients with HCC even after surgical resection.The overall curative effect of HCC is far from satisfaction.Cancer biotherapy has now truly matured into the fourth modality of cancer treatmnet and proved to be useful in conjunction with surgery,chemotherapy and radiotherapy.The purpose of this article is to review the current status and progress of cellular immunotherapy for HCC

Key words: Hepatocellular carcinoma, Cellular immunotherapy, Progress

CLC Number:

R735.7

YANG Fan, ZHANG Qi, CHEN Gui-hua. Cellular immunotherapy of hepatocellar carcinoma[J]. Surgical Research and New Technique, 2013, 2(4): 262-266.

References

[1]Bruix J,Boix L,Sala M,et al.Focus on hepatocellular carcinoma[J].Cancer cell,2004,5(3):215-219.
[2] 陈规划,张琪.肝癌生物治疗的现状与展望[J].外科理论与实践,2012,17(5):434-436.
[3] Schmidt-Wolf IG,Lefterova P,Mehta BA,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Experimental hematology,1993,21(13):1673-1679.
[4] Schmidt-Wolf IG,Negrin RS,Kiem HP,et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J].The Journal of experimental medicine,1991,174(1):139-149.
[5] Jiang J,Wu C,Lu B.Cytokine-induced killer cells promote antitumor immunity[J].Journal of translational medicine,2013,11(1):83.
[6] Huang ZM,Li W,Li S,et al.Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients[J].Journal of immunotherapy,2013,36(5):287-293.
[7] Cui J,Wang N,Zhao H,et al.Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma[J].International journal of cancer Journal international du cancer,2013.
[8] Ma Y,Xu YC,Tang L,et al.Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma:efficacy and safety[J].Experimental hematology & oncology,2012,1(1):11.
[9] Rosenberg SA,Spiess P,Lafreniere R.A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes[J].Science,1986,233(4770):1318-1321.
[10] Rosenberg SA,Packard BS,Aebersold PM,et al.Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.A preliminary report[J].The New England journal of medicine,1988,319(25):1676-1680.
[11] Shirabe K,Motomura T,Muto J,et al.Tumor-infiltrating lymphocytes and hepatocellular carcinoma:pathology and clinical management[J].International journal of clinical oncology,2010,15(6):552-558.
[12] Takayama T,Sekine T,Makuuchi M,et al.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial[J].Lancet,2000,356(9232):802-807.
[13] Gehring AJ,Xue SA,Ho ZZ,et al.Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines[J].Journal of hepatology,2011,55(1):103-110.
[14] Koh S,Shimasaki N,Suwanarusk R,et al.A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus[J].Molecular therapy Nucleic acids,2013,2(8):e114.
[15] Sadelain M,Brentjens R,Riviere I.The basic principles of chimeric antigen receptor design[J].Cancer discovery,2013,3(4):388-398.
[16] Han EQ,Li XL,Wang CR,et al.Chimeric antigen receptor-engineered T cells for cancer immunotherapy:progress and challenges[J].Journal of hematology & oncology,2013,6(1):47.
[17] Krebs K,Bottinger N,Huang LR,et al.T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice[J].Gastroenterology,2013,145(2):456-465.
[18] Klingemann HG.Cellular therapy of cancer with natural killer cells-where do we stand?[J].Cytotherapy,2013,15(10):1185-1194.
[19] 马杰.自然杀伤细胞与肿瘤免疫治疗研究进展[J].国际妇产科学杂志,2010,37(3):208-211.
[20] Geller MA,Miller JS.Use of allogeneic NK cells for cancer immunotherapy[J].Immunotherapy,2011,3(12):1445-1459.
[21] Jiang W,Zhang C,Tian Z,et al.hIFN-alpha gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function[J].Gene therapy,2013.
[22] Palucka K,Banchereau J.Cancer immunotherapy via dendritic cells[J].Nature reviews Cancer,2012,12(4):265-277.
[23] Palmer DH,Midgley RS,Mirza N,et al.A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J].Hepatology,2009,49(1):124-132.
[24] El Ansary M,Mogawer S,Elhamid SA,et al.Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J].Journal of cancer research and clinical oncology,2013,139(1):39-48.
[25] Tada F,Abe M,Hirooka M,et al.Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J].International journal of oncology,2012,41(5):1601-1609.NOTICE TO INVITE CONTRIBUTIONS
   See the announcement attached inside for the details of the journal newly established.
   Notices
   Your contributions are proposed to accord with the following requirements:
   1. The contents should be up to date, scientific and logical.the materials and data, reliable and correct,the thesis or topic, clear-cut,the texts,readable and fluent, as usual, less than 4000 characters,(tables and references excluded).
   The topics and abstracts are written both in Chinese and English. The abstracts should follow the form:Objective,Methods, Results and Conclusion.And the texts,the form: Introduction, Materials and Methods,Results and Discussion.
   2. Official introduction letter are needed to show the details:Your article is the only,public contribution to us, the names of authors are incontrovertible.
   3. On the first page of your article,the following information should be included: names of each author both in Chinese and Latin letters, the top degree of record of formal schooling, working unit,corresponding author’s name, address,telephone number, Email, length of text(count in character) and the numbers of table and figure.
   4. Attached with copies of documentaries concerned, if any, when your article referring to the programs or plans funded by the State administrations or joint partnership.
   5. References of the text are proposed to be not less than 10 items written in the form: if the journals concerned, order numbers, author’s names, title[J].journal names,year,volume,number,page numbers of the first and end pages. if the books cited: [book number]. Author’s names,title[M],edition,place,publishers and year.
   6. Double-submitted contributions are not welcome, if you want to change the publisher inform us before hand.
   7. The copyrights belong to the authors,but some limited literary or text corrections are necessary to edition. The author takes sole responsibility for his views. Attach your declaration with your article if you do not allow the contents or data to be cited or reprinted.
   8. Your article should be delivered via computer to cma1992@126.com. The frist author’s name,corresponding author’s address, the serial number, if the article corrected, are needed. The corrected copies should be mailed to us in time, otherwise,that means“cancellation by the author himself ”.
   9. The article is charged RMB50.00 per title for edition. Contribution fee will be paid according to the stipulations approved by the administration, a copy of the journal with your article inside will be given to you as a present.

Cellular immunotherapy of hepatocellar carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LIU Pengfei, XU Wen, LIU Kai, YE Chun. Differential diagnosis between atypical hepatic abscess and hepatocellular carcinoma [J]. Surgical Research and New Technique, 2019, 8(3): 187-188.
[2]	HAN Jinyan, DING Rongxia, DAI Linfeng. Progress on effects of enhanced recovery after surgery on 3D laparoscopic perioperative period [J]. Surgical Research and New Technique, 2019, 8(3): 216-219.
[3]	. Progress of the wrist nursing in patients undergoing coronary intervention from the transradial approach [J]. Surgical Research and New Technique, 2017, 6(1): 65-69.
[4]	. Comparative efficacy of radiofrequency ablation of small hepatocellular carcinoma TACE combined with sequential treatment with surgical resection [J]. Surgical Research and New Technique, 2016, 5(4): 237-240.
[5]	. Research Progress On Hip-reserving Surgerys Of The Femoral Head [J]. Surgical Research and New Technique, 2016, 5(4): 277-280,286.
[6]	. Progress in Surgical Treatment of Pelvic Organ Prolapse [J]. Surgical Research and New Technique, 2016, 5(1): 61-65.
[7]	. Advances in diagnosis and treatment of thyroid cancer based on molecular biology [J]. Surgical Research and New Technique, 2015, 4(3): 196-200.
[8]	. Surgical clinic status of phyllodes tumors [J]. Surgical Research and New Technique, 2015, 4(1): 4-8.
[9]	. research progresses of transcatheter therapies for mitral regurgitation [J]. Surgical Research and New Technique, 2014, 3(3): 157-160.
[10]	HAN Xu-jie, SHI Bao-min. Clinical progress of organ-preserving pancreatectomy [J]. Surgical Research and New Technique, 2014, 3(1): 46-49.
[11]	TANG Zhao-you. Approaches to improvement of survival after surgery for hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 213-215.
[12]	YE Shenglong. Multidisciplinary comprehensive therapy  for primary liver cancer [J]. Surgical Research and New Technique, 2013, 2(4): 216-218.
[13]	ZHAO Ze-ming, Becker Thomas, FAN Yue-zu, Ringe Bastian, Klempnauer Jürgen. Hepatocellular carcinoma (HCC) & liver transplantation (LT) [J]. Surgical Research and New Technique, 2013, 2(4): 219-224.
[14]	WANG Jie. Anti-HBV playing an important role in therapy of hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 225-228.
[15]	ZHAN Wan-guang, ZHANG Bi-xiang. Treatment strategies based on evaluation of staging systems for hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 251-254.